Clinical Trials
1,911 trialsA Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
STELLAR-002
Exelixis
MK-3475-04A
Merck Sharp & Dohme LLC
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
National Cancer Institute (NCI)
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
SURGE Therapeutics
PSMA-DC
Novartis
MK-5684-004
Merck Sharp & Dohme LLC
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Telix Pharmaceuticals (Innovations) Pty Limited
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
PSMAcTION
Novartis
CAPT CTC
Institut Claudius Regaud
Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
Ottawa Hospital Research Institute
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Effects of Rectal Indomethacin Suppository on Postoperative CRBD in Patients Undergoing LRP
Zhejiang University
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
National Institutes of Health Clinical Center (CC)
ASCaP
Jonsson Comprehensive Cancer Center
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification
Jonsson Comprehensive Cancer Center
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
National Cancer Institute (NCI)
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
MK-5684-01A
Merck Sharp & Dohme LLC
ProTACT
Full-Life Technologies GmbH
SHAPE-PSMA
University Health Network, Toronto
STARLiT
Case Comprehensive Cancer Center
MK-3475-03C
Merck Sharp & Dohme LLC
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
National Cancer Institute (NCI)
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Bristol-Myers Squibb
23146
Bayer
MK-6482-043
Merck Sharp & Dohme LLC
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
Tianjin Medical University Second Hospital
LITESPARK-034
Merck Sharp & Dohme LLC
LORUP
Umeå University
Frailty in Older Adults With Prostate Cancer: a Prospective Cohort Study
University of Limerick
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
National Institutes of Health Clinical Center (CC)
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
National Institutes of Health Clinical Center (CC)
IRONMAN
Prostate Cancer Clinical Trials Consortium
En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
National Institutes of Health Clinical Center (CC)
VERDI
Dana-Farber Cancer Institute
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Oncorena AB
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
National Institutes of Health Clinical Center (CC)
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Institutes of Health Clinical Center (CC)
RECOVER
Comprehensive Cancer Centre The Netherlands
Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
National Institutes of Health Clinical Center (CC)
NEXUS-01
Eli Lilly and Company
ABLE-32
Ferring Pharmaceuticals
ABLE-22
Ferring Pharmaceuticals
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Kyntra Bio
MK-2400-001
Merck Sharp & Dohme LLC